BRAF and colorectal carcinoma: Collectively, our results show that CRC resistance to EGFR inhibitors stems primarily from the inability of the inhibitors to downregulate EGFR, rather than mutations in EGFR, KRAS, BRAF and PIK3CA, and suggest that a therapeutic strategy centered on PEPDG278D is highly promising for overcoming drug resistance in CRC.